The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Triple-negative breast cancer subtypes and pathologic complete-response rate to neoadjuvant chemotherapy: Results from the GEICAM/2006-2003 study.
Angela Santonja
No relevant relationships to disclose
Joan Albanell
No relevant relationships to disclose
Jose Ignacio Chacon
No relevant relationships to disclose
Ana Lluch
No relevant relationships to disclose
Alfonso Sanchez-Muñoz
No relevant relationships to disclose
Federico Rojo
No relevant relationships to disclose
Antonio Anton
No relevant relationships to disclose
Laura G. Estevez
No relevant relationships to disclose
Beatriz Cirauqui
No relevant relationships to disclose
V. de Luque
No relevant relationships to disclose
Lourdes Calvo
No relevant relationships to disclose
Miguel Angel Seguí-Palmer
No relevant relationships to disclose
Arrate Plazaola
No relevant relationships to disclose
Sonia Gonzalez
No relevant relationships to disclose
Ana Santaballa
No relevant relationships to disclose
Juan de la Haba-Rodriguez
No relevant relationships to disclose
Cesar Rodriguez
No relevant relationships to disclose
Rosalia Caballero
No relevant relationships to disclose
Eva Maria Carrasco
No relevant relationships to disclose
Emilio Alba
No relevant relationships to disclose